PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Explore how portfolio size and sector exposure differ between these two small-cap ETFs, each offerin

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

Bernstein analyst Eve Burstein reinstates Guardant Health (NASDAQ:GH) with a Outperform and annou

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 b

Not intended for distribution to U.S. newswire services or for dissemination in the U.S. Red Deer, A

Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced

RBC Capital analyst Dan Leonard initiates coverage on Guardant Health (NASDAQ:GH) with a Outperfo

Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEX

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises

Goldman Sachs analyst Evie Koslosky initiates coverage on Guardant Health (NASDAQ:GH) with a Buy

This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.

Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H

Top Wall Street analysts upgraded GH to Outperform and raised price target to $160. Other analysts a

Wolfe Research analyst Mike Polark assumes Guardant Health (NASDAQ:GH) with a Outperform rating a

Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued

Evercore ISI Group analyst Vijay Kumar upgrades Guardant Health (NASDAQ:GH) from In-Line to Outpe

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the compan

New performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer c

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Guardant Health stock spiked Wednesday after the American Cancer Society recommended its blood test

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-app

Updated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are n

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Quantum computing, AI and semiconductor-linked stocks dominated last week's large-cap gainers as

The U.S. Food and Drug Administration (FDA) on Wednesday approved Guardant Health Inc.'s (NASDAQ:GH)

Guardant Health secured FDA approval for Guardant360 Liquid CDx, expanding blood-based cancer profil

The Food and Drug Administration approved Guardant Health's newest blood cancer test Wednesday, and

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U

Guardant Health's new FDA-approved liquid biopsy integrates genomic and epigenomic insights to p

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

Guardant Health, Inc. delivered strong results in the first quarter, with accelerating revenue growt

Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and rais

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a In-Line

2026 GuidanceGuardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.45) per share which beat the analyst co

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment fo

VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults

The collaboration reflects the growing importance of precision diagnostics in oncology drug developm

FDA highlights concerns over camizestrant data, questioning PFS relevance, OS maturity, and benefit-

Macro concerns, AI competition, and analyst downgrades drove broad weekly losses across software and